Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
A phase 1/2 trial of Fulvestrant, Abemaciclib in ovarian cancer and metastatic cancer, run by Incyclix Bio, now recruiting.
Overview
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT05735080 by Incyclix Bio, with 150 participants planned, started 2023-03-28 and due to reach its primary completion in 2027-07. Interventions recorded: INX-315, Fulvestrant, Abemaciclib. Conditions listed: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Fulvestrant.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread).